Eagle Pharmaceuticals, Inc. (13)

Browse by Contract Category

Contracts

License Agreement, dated as of August 6, 2021, between the Registrant and AOP Orphan Pharmaceuticals GmbH (Filed With SEC on November 9, 2021)
Form of Performance Stock Unit Grant Package (2014 Equity Incentive Plan) (Filed With SEC on March 5, 2021)
Co-Promotion Agreement, dated January 7, 2020, between the Registrant and Tyme Technologies Inc (Filed With SEC on May 11, 2020)
Fifth Amendment to Lease Agreement between the Registrant and CAPSTONE TICE BLVD LLC. dated as of August 8, 2019 (Filed With SEC on March 2, 2020)
Settlement Agreement, by and between the Registrant and Eli Lilly and Company, dated December 13, 2019 (Filed With SEC on March 2, 2020)
Securities Purchase Agreement, dated January 7, 2020, between the Company and Tyme (Filed With SEC on January 8, 2020)
License Agreement, dated as of August 19, 2021, between the Registrant and Combioxin SA (Filed With SEC on November 9, 2021)
Form of Performance Stock Unit Grant Package (2014 Equity Incentive Plan) (Filed With SEC on March 5, 2021)
Consulting Agreement between (Filed With SEC on November 2, 2020)
Description of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 2, 2020)
Co-Promotion Agreement with Tyme Technologies, Inc., dated January 7, 2020 (Filed With SEC on March 2, 2020)
Eagle Pharmaceuticals, Inc. Amended and Restated Severance Benefit Plan (Filed With SEC on December 16, 2019)
Fourth Amendment to the Exclusive License Agreement, dated April 12, 2019, by and between Eagle Pharmaceuticals, Inc., a Delaware corporation and Teva Pharmaceuticals... (Filed With SEC on May 7, 2019)